RT Journal Article
SR Electronic
T1 Genomic epidemiology of the SARS-CoV-2 epidemic in Zimbabwe: Role of international travel and regional migration in spread
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.04.20232520
DO 10.1101/2021.01.04.20232520
A1 Mashe, Tapfumanei
A1 Takawira, Faustinos Tatenda
A1 Martins, Leonardo de Oliveira
A1 Gudza-Mugabe, Muchaneta
A1 Chirenda, Joconiah
A1 Munyanyi, Manes
A1 Chaibva, Blessmore V
A1 Tarupiwa, Andrew
A1 Gumbo, Hlanai
A1 Juru, Agnes
A1 Nyagupe, Charles
A1 Phiri, Isaac
A1 Manangazira, Portia
A1 Goredema, Alexander
A1 Danda, Sydney
A1 Chabata, Israel
A1 Jonga, Janet
A1 Munharira, Rutendo
A1 Masunda, Kudzai
A1 Mukeredzi, Innocent
A1 Mangwanya, Douglas
A1 ,
A1 ,
A1 Trotter, Alex
A1 Viet, Thanh Le
A1 Kay, Gemma
A1 Baker, David
A1 Thilliez, Gaetan
A1 Gutierrez, Ana-Victoria
A1 O’Grady, Justin
A1 Hove, Maxwell
A1 Mutapuri-Zinyowera, Sekesai
A1 Page, Andrew J.
A1 Kingsley, Robert A.
A1 Mhlanga, Gibson
YR 2021
UL http://medrxiv.org/content/early/2021/01/06/2021.01.04.20232520.abstract
AB Zimbabwe reported its first case of SARS-Cov-2 infection in March 2020, and case numbers increased to more than 8,099 to 16th October 2020. An understanding of the SARS-Cov-2 outbreak in Zimbabwe will assist in the implementation of effective public health interventions to control transmission. Nasopharyngeal samples from 92,299 suspected and confirmed COVID-19 cases reported in Zimbabwe between 20 March and 16 October 2020 were obtained. Available demographic data associated with those cases identified as positive (8,099) were analysed to describe the national breakdown of positive cases over time in more detail (geographical location, sex, age and travel history). The whole genome sequence (WGS) of one hundred SARS-CoV-2-positive samples from the first 120 days of the epidemic in Zimbabwe was determined to identify their relationship to one another and WGS from global samples. Overall, a greater proportion of infections were in males (55.5%) than females (44.85%), although in older age groups more females were affected than males. Most COVID-19 cases (57 %) were in the 20-40 age group. Eight lineages, from at least 25 separate introductions into the region were found using comparative genomics. Of these, 95% had the D614G mutation on the spike protein which was associated with higher transmissibility than the ancestral strain. Early introductions and spread of SARS-CoV-2 were predominantly associated with genomes common in Europe and the United States of America (USA), and few common in Asia at this time. As the pandemic evolved, travel-associated cases from South Africa and other neighbouring countries were also recorded. Transmission within quarantine centres occurred when travelling nationals returning to Zimbabwe. International and regional migration followed by local transmission were identified as accounting for the development of the SARS-CoV-2 epidemic in Zimbabwe. Based on this, rapid implementation of public health interventions are critical to reduce local transmission of SARS-CoV-2. Impact of the predominant G614 strain on severity of symptoms in COVID-19 cases needs further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a combination of routine work of scientists at the National Microbiology Reference Laboratory, Biomedical Research and Training Institute, Beatrice Road Infectious Diseases Hospital, National Virology Laboratory and National TB Reference Laboratory The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); this research was funded in part by the BBSRC Institute Strategic Programme Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, and BBS/E/F/000PR10352 and by the Quadram Institute Bioscience BBSRC funded Core Capability Grant (project number BB/CCG1860/1). The COVID-19 Genomics UK (COG-UK) Consortium is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was exempted by the Medical Research Council of Zimbabwe as this study was in response to a public health emergency.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available